TITLE

GENEREX GETS CHINA PATENT FOR II-KEY PETIDE VACCINE

PUB. DATE
April 2010
SOURCE
Worldwide Biotech;Apr2010, Vol. 22 Issue 4, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that Generex Biotechnology Corp. has received a patent for its Ii-Key peptide vaccine technology in China. The company has begun discussions for potential joint venture/licensing partnerships with pharmaceutical companies for its peptide cancer vaccine technology platform. The company has also published the results from its Phase II trial of an Ii-Key modified peptide vaccine for treating patients with breast cancer.
ACCESSION #
48899738

 

Related Articles

  • GENEREX AWARDED PATENTS IN NORTH AND SOUTH AMERICA.  // Worldwide Biotech;Apr2008, Vol. 20 Issue 4, p7 

    The article announces that Generex Biotechnology Corp. has received patents in Canada and Argentina. The Canadian Intellectual Property Office has granted Generex a patent that contains process, formulation and use claims to a mixed micellar pharmaceutical formulation for buccal administration,...

  • Generex Biotech receives new patents for buccal applications.  // Medical Device Daily;6/15/2009, Vol. 13 Issue 113, p10 

    The article reports on the five patents in Canada, Australia, New Zealand, Brazil and Lebanon received by Generex Biotechnology. Additional protection for Generex's proprietary compositions and methodologies for delivering pharmaceuticals in buccal applications is provided by the patents. It is...

  • AACR Roundup.  // BioWorld Today;4/5/2011, Vol. 22 Issue 65, p8 

    The article focuses on the study data presented by Generex Biotechnology Corp. at the annual meeting of the American Association for Cancer Research (AACR) on the effect of a peptide vaccine on a subgroup of CD4-positive cells can suppress immune responses.

  • ASCO 2013.  // BioWorld Today;6/3/2013, Vol. 24 Issue 105, p7 

    The article discusses data for li-Key modified HER2 peptide vaccine presented by Generex Biotechnology Corp. at the American Society of Clinical Oncology (ASCO) meeting held in Chicago, Illinois in June 2013.

  • GENEREX AWARDED TWO NEW PATENTS FOR BUCCAL DRUG DELIVERY.  // Biotech Business;Jul2010, Vol. 23 Issue 7, p7 

    The article reports that Generex Biotechnology Corporation was awarded patents in Japan and Ukraine. According to Rose C. Perri, the company's chief operating officer, each patent issuance suggests the inventiveness of the company's buccal drug delivery platform technologies. Generex is based in...

  • Financings Roundup.  // BioWorld Today;5/21/2009, Vol. 20 Issue 97, p10 

    The article reports on the consummation by Generex Biotechnology Corp. of a $5 million registered direct offering of the company's common stock to selected accredited investors. The offering of the company's common stock is said to have been at discount, had no warrant coverage and covers about...

  • Clinic Roundup.  // BioWorld Today;5/23/2013, Vol. 24 Issue 99, p8 

    This section offers updates on biotechnology sector clinical progress as of May 23, 2013. Acelrx Pharmaceuticals Inc. reported on the results of a Phase III study with its Sufentanil NanoTab patient-controlled analgesia (PCA) system. Agenus Inc. announced the start of a Phase II study with a...

  • American Society of Clinical Oncology.  // BioWorld International;6/3/2009, Vol. 14 Issue 22, p5 

    The article focuses on the results of the Phase I trial of AE37 cancer vaccine presented by Generex Biotechnology Corp. at the annual meeting of the American Society of Clinical Oncology (ASCO) in the U.S. in May 2009. Results indicated that the vaccine is well tolerated and can drive immune...

  • CLINIC ROUNDUP.  // BioWorld Today;2/13/2014, Vol. 25 Issue 30, p7 

    This section offers news briefs on clinical studies by biopharmaceutical companies as of February 13, 2014. Generex Biotechnology Corp. reported results from a phase II study of AE37 cancer vaccine for preventing relapse in breast cancer patients. Omeros Corp. reported that OMS824 achieved...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics